Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of ASP7374 in Healthy Adults
NCT01393951Phase 2Completed
- Sponsor
- UMN Pharma Inc.
- Start
- May 2011
- Primary completion
- Dec 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASP7374 in influenza (3 arms), sponsored by UMN Pharma Inc. Primary endpoints: Hemagglutination Inhibition Antibody Titer at Day 29, Incidence of Adverse Events and 2 more. Started May 2011; status: completed.
02
Drugs
ASP7374
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01393951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01393951.